Novoa-Vargas A

Idioma: Español
Referencias bibliográficas: 29
Paginas: 613-622
Archivo PDF: 512.39 Kb.

RESUMEN

El cáncer de ovario es una enfermedad cargada de paradigmas y un problema grave de salud. Importa conocer su historia natural, pues es de origen multifactorial, y entender su comportamiento desde sus factores de riesgo, hasta la muerte por sus metástasis en el huésped sigue siendo un reto para el grupo oncológico. Se efectuó una revisión bibliográfica analítica para actualizar los conceptos más recientes de su origen, evolución, factores de riesgo, horizonte preclínico y sus manifestaciones clínicas; hasta llegar al deceso casi inminente del huésped.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. Globocan.iarc.fr (accessed 23 January 2013.

2. Hannibal CG. Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five year relative survival. Acta Obstetricia et Gynecologica Scandinavica 2008; 87(12):1353–60.

3. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al and the EUROCARE Working Group. EUROCARE- 3: survival of cancer patients diagnosed 1990-94 - results and commentary. Annals of Oncology 2003;14 Suppl 5:v61–v118.

4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T. Cancer statistics. CA: A Cancer Journal for Clinicians 2008;58:71–96.

5. Chan JK, Cheung MK, Husain A, et al. Patterns a progress in ovarian cancer over 14 years. Obstet Gynecol 2006;108:521-528.

6. Gallardo-Rincón, et al. Tercer consenso Nacional de Cáncer de ovario 2011- Rev Invest Clin, 2001;63(6):665-702.

7. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology. Vol. Fascicle 23 3rd series, Washington, DC: Armed Forces Institute of Pathology, 1998:1–168.

8. Ovary. In: American Joint Committee on Cancer: AJCC Cancer Staging manual. 6th ed. New York, NY: Springer;2002, p. 275-84.

9. American cáncer Society. Cancer Facts and Figures 2008. Atlanta Ga. Am Cancer Soc 2008.

10. Reporte Histopatológico de Neoplasias Malignas 2003.

11. Geomini Peggy, Kruitwagen Roy, Bremer Gérard, et al. The accuracy of risks scores in prediciting ovarian malignancy, a sistemic review. Obst Gynecol 2009;113(2):384-394.

12. Amstrong D. Bundy Wentzel L., Huang H Baerger R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cáncer. N Engl J Med 2006;354: 34-43.

13. Engel J, Eckel R, Schubert-Firstchle G, et al. Moderate progress for ovarian cancer in the last 20 years; prolongation of survival, but no improvement in the cure rate. Eur J Cancer 2002;38:2435-45.

14. Herráez Ángel. Biología molecular e ingeniería genética. 2ª edición. Elsevier, España 2012. Cap. 26 en Bases moleculares del cáncer. Pp: 449-479.

15. Riman T, Dickman PW, Nilsson S , et al. Risk factores for inasioveepithelial ovarian cáncer: result from a Swedish case-control study. Am J Epidemio 2002;156:363-73.

16. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a casae congrol study. Br J Cancer 1989;60:592-8.

17. Brinton Louise A, Moghissi Kamran S, Westhoff Carolyn L, et al. Cancer risk among infertile women with androgen excess or menstrual disorders including polycystic ovary syndrome. Fertility and Sterility 2010;94:1787-1792.

18. Risch H, Marett L, Howe G. Parity, contracepcion, infertility and risk of epithelial ovarian cancer. Am J Epidemiol 1994;140(7):585-97.

19. Yoshida Hiroyuki, Liu Jinsong, Samuel Shaija, et al. Steroid receptor coactivator-3, a homolog of taiman that controls cell migration in the drosophila ovary, regulates migration of human ovarian cancer cells. Molecular and Cellular Endocrinology 2005; 245:77-85.)

20. Stammer Karen, Edassery Seby L, Barua Animesh, et al. Selenium- binding protein, expression in ovaries and ovarian tumors in the laying hen and spontaneous model of human ovarian cancer. Gynecologic Oncology 2008, 109:115-121.

21. Allahbadia Gautam N, Merchant Rubina. Polycystic Ovary Syndrome and Impact on Health. Middle East Fertility Society Journal 2011;16:19-37), (Diaz Gomez M.I, Tamayo Daniel, Castro Jose A. Nitrosodimethylamine Metabolism in Rat Ovaries. Interactions of Its metabolites with Nucleic Acids and Proteins,Cancer Letters 1998; 41:257-263.

22. Herrera Gómez Ángel, Gallardo Rincón Dolores. Manual de oncología, InCan, en Cap. 54 Cáncer epitelial del ovario pp:410- 26. McGraw-Hill Interamericana SA de CV. 2000, México.

23. Farghaly Samir A. The role of oral contraceptives pills(OCPs) in chemoprevention fo epitelial ovarian cáncer in women with mutant BRCA1 and BRCA2 genes. J Cancer Sci Ther2013;5(8):1000-124.

24. Dodge Je, Covens Al, Lachetti C, et al. Management of a suspicious adnexal mass: a clinical practice guidline. Curr Oncol, 2012; 19(4):244-57.

25. Romagnolo C, Gadducci A, Sartori et al. Management of borderline ovarian tumors: results of an Italian multicenter study. Gynecol Oncol 2006;101:255-60.

26. Park JY, Kim DY, Kim JH. Surgical management of borderline ovarian tumors: the role of fertility-sparing surgery. Gynecol Oncol 2009;113:75-82.

27. Desfeux P, Camatte S. Chatellier G et al. Impact of surgical approach on the management of macroscopic early ovarian borderline tumors. Gynecol Oncol 2005;98:390-5.

28. Escudero DP, Torres LA. Neoplasias malignas de células germinales del ovario. En: Cáncer ginecológico, diagnóstico y tratamiento. 1ª edición. Cap. 23. México: Mc Graw Hill; 2004. p. 221-232.

29. Malpica A. Grading of ovarian cáncer. Int J Gynecol Pathol 2008;27:175-81.